Blood 2011,117(11):3002–3009.PubMedCrossRef 4. Sun CL, Francisco L, Kawashima
T, Leisenring W, Robison LL, Baker KS, Weisdorf DJ, Forman SJ, Bhatia S: Prevalence and predictors of chronic health conditions after hematopoietic cell transplantation: a report from the Bone Marrow Transplant Survivor Study. Blood 2010,116(17):3129–3139.PubMedCrossRef 5. Cardinale D, Sandri MM: Role of biomarkers in chemotherapy-induced cardiotoxicity. Prog Cardiovasc Dis 2010,53(2):121–129.PubMedCrossRef 6. Palladini G, Merlini G: Transplantation vs conventional-dose therapy for amyloidosis. Curr Opin Oncol 2011,23(2):214–220.PubMedCrossRef 7. Coghlan JG, Handler CE, Kottaridis PD: CB-5083 in vitro https://www.selleckchem.com/products/Lapatinib-Ditosylate.html cardiac assessment of patients for haematopoietic stem cell transplantation. Best Pract Res Clin Haematol 2007, 20:247–263.PubMedCrossRef 8. Herman EH, Zhang J, Lipshultz SE, Rifai N, Chadwick D, Takeda K, Yu ZX, Ferrans https://www.selleckchem.com/products/Neratinib(HKI-272).html VJ: Correlation between serum levels of cardiac troponin-T and the severity of the chronic cardiomyopathy induced by doxorubicin. J Clin Oncol 1999,17(7):2237–2243.PubMed 9. Januzzi JL, Van Kimmenade R, Lainchbury J, Bayes-Genis A, Ordonez-Llanos J, Santalo-Bel M, Pinto YM, Richards M: NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients: the International Collaborative of NT-proBNP Study.
Eur Heart J 2006, 27:330–337.PubMedCrossRef 10. Snowden JA, Hill GR, Hunt P, Carnoutsos S, Spearing RL, Espiner E, Hart DN: Assessment of cardiotoxicity during haemopoietic stem cell transplantation with plasma brain natriuretic
peptide. Bone Marrow Transplant 2000, 26:309–313.PubMedCrossRef 11. Niwa N, Watanabe E, Hamaguchi M, Kodera Y, Miyazaki H, Kodama I, Ohono M: Early and late elevation of plasma atrial and brain natriuretic peptides in patients after bone marrow transplantation. Ann Hematol 2001, 80:460–465.PubMedCrossRef 12. Masuko Meloxicam M, Ito M, Kurasaki T, Yano T, Takizawa J, Toba K, Aoki S, Fuse I, Kodama M, Furukawa T, Aizawa Y: Plasma brain natriuretic peptide during myeloablative stem cell transplantation. Intern Med 2007, 46:551–555.PubMedCrossRef 13. Horacek JM, Pudil R, Tichy M, Jebavy L, Zak P, Slovacek L, Maly J: Biochemical markers and assessment of cardiotoxicity during preparative regimen and hematopoietic cell transplantation in acute leukemia. Exp Oncol 2007, 29:343–347. 14. Sandri MT, Salvatici M, Cardinale D, Zorzino L, Passerini R, Lentati P, Leon M, Civelli M, Martinelli G, Cipolla CM: N-terminal pro-B-type natriuretic peptide after high-dose chemotherapy: a marker predictive of cardiac dysfunction? Clin Chem 2005, 51:1405–1410.PubMedCrossRef 15. Rr P, Libby P: Inflammation in atherosclerosis: from vascular biology to biomarker discovery and risk prediction. Clin Chem 2008, 54:24–38. 16. Bujak M, Frangogiannis NG: The role of IL-1 in the pathogenesis of heart disease.